challenges associated with convalescent plasma infusion therapy during pregnancy, a case report

Introduction: the covid-19 pandemic has so far been characterized by significant morbidity and a high mortality rate worldwide. people who are frail due to age and / or the presence of comorbidities, including pregnant women, are exposed to a greater risk of developing a very serious disease. however, only recently, certain experimental studies have focused on the role of anti- covid-19 drugs during pregnancy. convalescent plasma (cp), derived from the people who recover from covid-19, can represent an interesting therapeutic option for improving the antiviral immune response, owing to its specific neutralizing content and different immune mediators against sarscov-2. it can also improve the survival of the patients who are diagnosed with the disease early and treated in the primary stages of the disease. case presentation: we reported the case of a pregnant patient safely treated with cp at our hospital and conducted a comprehensive literature search using extensive database for similar case reports published from february 12, 2020 to may 31, 2021. conclusions: an extensive literature search documented the publication of a limited number of case reports concerning covid-19 hyperimmune plasma treatment (cpt) during pregnancy. the available results are not homogeneous; however, a very early use of cpt may possibly be effective in pregnancy. the evolution of covid-19-related pneumonia, due to a reduction in both viremia and the concentration of proinflammatory cytokines, can be positively influenced by cpt, together with the standards of care treatment.